ImmunityBio マネジメント
マネジメント 基準チェック /34
ImmunityBioの CEO はRich Adcockで、 Oct2020年に任命され、 の在任期間は 5.75年です。 の年間総報酬は$ 12.72Mで、 6.5%給与と93.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.054%を直接所有しており、その価値は$ 5.29M 。経営陣と取締役会の平均在任期間はそれぞれ5年と5.9年です。
主要情報
Rich Adcock
最高経営責任者
US$12.7m
報酬総額
| CEO給与比率 | 6.54% |
| CEO在任期間 | 5.8yrs |
| CEOの所有権 | 0.05% |
| 経営陣の平均在職期間 | 5yrs |
| 取締役会の平均在任期間 | 5.9yrs |
経営陣の近況
Recent updates
ナラティブの更新 • Jun 26
IBRX: Potential Index Inclusion Will Support Cancer Franchise Expansion
Analysts have lowered their ImmunityBio price target slightly from $13.50 to $13.00 as they refresh assumptions around discount rates, revenue growth, margins, and future P/E expectations. What’s in the News for ImmunityBio Retail traders are speculating that ImmunityBio stock could shift from the Russell 2000 to the Russell 1000 based on a cutoff around US$5.7b, with some traders expecting potential index fund buying and changes in volatility if inclusion occurs, according to recent Stocktwits sentiment data and after hours trading moves.Seeking Alpha • May 20
ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout
Summary ImmunityBio is transitioning into a scalable bladder cancer immunotherapy platform, driven by accelerating Anktiva adoption and robust revenue growth. 1Q26 revenue surged 168% YoY to $44.2M, with strong physician uptake, but operating expenses and adjusted net loss ($86.2M) remain elevated amid heavy investment. The papillary sBLA for Anktiva is a key near-term catalyst; regulatory uncertainty persists, but compelling QUILT-3.032 data and prior FDA approval in CIS support optimism. The Tokyo-172 BCG deal positions IBRX to resolve U.S. supply bottlenecks, enabling dual-source BCG infrastructure and global expansion, enhancing platform value. Read the full article on Seeking Alpha分析記事 • May 11
Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...
新しいナラティブ • Apr 01
Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Mar 18
Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?新しいナラティブ • Mar 04
Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?分析記事 • Aug 07
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
NasdaqGS:IBRX 1 Year Share Price vs Fair Value Explore ImmunityBio's Fair Values from the Community and select yours A...Seeking Alpha • Apr 29
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking AlphaSeeking Alpha • Jan 17
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
Summary ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but recent product sales and supportive financing extend the cash runway, providing a potential growth opportunity. Strengths include data supporting new approvals and expanding Anktiva's market, though risks involve unclear lung cancer market size and significant liabilities. Upgrading IBRX stock to “Buy” due to likely 2025 catalysts: accelerating Anktiva sales, potential lung cancer approval, and expanding bladder cancer market. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$855m |
| Dec 31 2025 | US$13m | US$832k | -US$351m |
| Sep 30 2025 | n/a | n/a | -US$349m |
| Jun 30 2025 | n/a | n/a | -US$367m |
| Mar 31 2025 | n/a | n/a | -US$409m |
| Dec 31 2024 | US$11m | US$802k | -US$414m |
| Sep 30 2024 | n/a | n/a | -US$588m |
| Jun 30 2024 | n/a | n/a | -US$598m |
| Mar 31 2024 | n/a | n/a | -US$601m |
| Dec 31 2023 | US$1m | US$796k | -US$583m |
| Sep 30 2023 | n/a | n/a | -US$458m |
| Jun 30 2023 | n/a | n/a | -US$473m |
| Mar 31 2023 | n/a | n/a | -US$430m |
| Dec 31 2022 | US$4m | US$791k | -US$417m |
| Sep 30 2022 | n/a | n/a | -US$400m |
| Jun 30 2022 | n/a | n/a | -US$376m |
| Mar 31 2022 | n/a | n/a | -US$370m |
| Dec 31 2021 | US$29m | US$765k | -US$347m |
| Sep 30 2021 | n/a | n/a | -US$323m |
| Jun 30 2021 | n/a | n/a | -US$301m |
| Mar 31 2021 | n/a | n/a | -US$264m |
| Dec 31 2020 | US$843k | US$141k | -US$222m |
報酬と市場: Richの 総報酬 ($USD 12.72M ) は、 US市場 ($USD 14.46M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Richの報酬は増加しましたが、会社は利益を上げていません。
CEO
Rich Adcock (57 yo)
5.8yrs
在職期間
US$12,716,953
報酬
Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 11.7yrs | US$12.29m | 27.83% $ 2.8b | |
| President | 5.8yrs | US$12.72m | 0.053% $ 5.3m | |
| Chief Financial Officer | 7yrs | US$4.24m | 0.029% $ 2.8m | |
| Chief Accounting Officer | 4.7yrs | US$745.31k | 0.011% $ 1.1m | |
| Chief Corporate Affairs Officer & Director | 5.3yrs | データなし | 0.27% $ 26.5m | |
| Chief Technology Officer | 3.5yrs | データなし | データなし | |
| Chief Communications Officer & Head of Patient Advocacy | 6.3yrs | データなし | データなし | |
| Senior Vice President of Human Resources | 5yrs | データなし | データなし | |
| Chief Medical Officer of Liquid Tumors & Cell Therapy | 1.4yrs | データなし | データなし | |
| Chief Medical Officer | 5.9yrs | データなし | データなし | |
| Chief Science Officer of Cellular | no data | データなし | データなし | |
| Senior VP of Product Development & Cell Therapy Program | 2.5yrs | データなし | データなし |
5.0yrs
平均在職期間
59yo
平均年齢
経験豊富な経営陣: IBRXの経営陣は経験豊富で経験豊富です（平均在職期間は5年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 11.7yrs | US$12.29m | 27.83% $ 2.8b | |
| President | 5.3yrs | US$12.72m | 0.053% $ 5.3m | |
| Chief Corporate Affairs Officer & Director | 19.5yrs | データなし | 0.27% $ 26.5m | |
| Independent Director | 5.9yrs | US$477.28k | 0% $ 0 | |
| Independent Director | 5.4yrs | US$470.59k | 0.00076% $ 75.1k | |
| Independent Director | less than a year | US$302.74k | データなし | |
| Independent Director | 11yrs | US$513.38k | 0.025% $ 2.5m | |
| Lead Independent Director | 7.1yrs | US$514.19k | 0.019% $ 1.9m | |
| Independent Director | 5.3yrs | US$489.19k | 0% $ 0 |
5.9yrs
平均在職期間
71yo
平均年齢
経験豊富なボード: IBRXの 取締役会 は 経験豊富 であると考えられます ( 5.9年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/05 09:53 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
ImmunityBio, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6
| アナリスト | 機関 |
|---|---|
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |